November 08, 2012

ITCA 650 for Zero-Order Continuous Delivery of Exenatide at Therapeutic Levels Using 3-, 6-, and 12-Month Mini-pumps

November 08, 2012

Precise and Contiuous Subcutaneous Delivery of Exenatide with ITCA 650 Provides Consistent and Sustained Glycemic Control in Metformin-Treted Type 2 Diabetes

October 03, 2012

EASD 2012: Optimizing Phase 3 Dose Selection with ITCA 650

September 14, 2011

ITCA 650 48 week Phase 2 oral presentation EASD 2011

September 14, 2011

PK/PD of ITCA 650 in Subjects with Type 2 Diabetes

September 14, 2011

Improved Patient Satisfaction with ITCA 650 vs. Exenatide Injections

June 28, 2011

ITCA 650 Phase 2 oral presentation from ADA 2011

September 22, 2010

ITCA 650 Phase 2 oral presentation EASD 2010

June 28, 2010

Comparing ITCA 650, Continuous Subcutaneous Delivery of Exenatide Via DUROS Device, vs Twice Daily Exenatide Injections in Metformin-Treated Type 2 Diabetes

November 06, 2009

Stability of ITCA 650 for Continuous Subcutaneous Delivery of Exenative at Body Temperature for 12 Months

November 06, 2009

Continuous Subcutaneous Delivery of Exenative via ITCA 650 Lowers Plasma Glucose, HbA1c and Reduces Weight in a 28-day Phase 1b Study in Type 2 Diabetes

September 30, 2009

EASD Presentation: A Phase 1b Study of ITCA 650: Continuous Subcutaneous Delivery of Exenatide via DUROS Device Lowers Fasting and Postprandial Plasma Glucose

June 06, 2009

ADA 2009 Late Breaker: A Phase 1b Study of ITCA 650: Continuous Subcutaneous Delivery of Exenatide via DUROS Device Lowers Fasting and Postprandial Plasma Glucose

November 18, 2008

Intarcia Therapeutics, Inc. Presents DUROS Delivery of Hepatitis C and type 2 diabetes therapies at AAPS conference

May 01, 2008

DUROS® Technology Delivers Pepties and Proteins at Consistent Rate Continuously for 3 to 12 Months